ARVN three-lens brief
Evidence-based stock research on ARVN. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 7% of its 52-week range — deep in the lower band.
- Trading at 7% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 10.4pp over 30 days.
- Analyst mean target $14.00 — 103% above current (13 analysts).
- Negative free cash flow last quarterly (-$46.58M).
ARVN closed at $6.91 (-0.14%) as of 2026-11-12. Market cap: $452.50M. P/E (trailing) 28.9. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $14.00 — 103% above current (13 analysts).. Concerns: trading at 7% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $500.0K, net income -$53.90M, free cash flow -$46.58M.
Why three lenses on ARVN, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ARVN across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ARVN" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ARVN brief"></iframe>